vs

Side-by-side financial comparison of INNOVATIVE SOLUTIONS & SUPPORT INC (ISSC) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

INNOVATIVE SOLUTIONS & SUPPORT INC is the larger business by last-quarter revenue ($21.8M vs $12.5M, roughly 1.7× Avidity Biosciences, Inc.). INNOVATIVE SOLUTIONS & SUPPORT INC runs the higher net margin — 18.6% vs -1398.3%, a 1416.9% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 36.6%). INNOVATIVE SOLUTIONS & SUPPORT INC produced more free cash flow last quarter ($7.0M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 42.5%).

Motorola Solutions, Inc., is an American technology company that provides safety and security products and services. Headquartered in Chicago, Illinois, the company provides critical communications, video security, and command center technologies, used by public safety agencies and enterprises. It was formed in 2011 by the division of Motorola, Inc., and is its legal successor; the former company's mobile phone division was spun off as Motorola Mobility, now part of Chinese technology company...

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

ISSC vs RNA — Head-to-Head

Bigger by revenue
ISSC
ISSC
1.7× larger
ISSC
$21.8M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+397.5% gap
RNA
434.0%
36.6%
ISSC
Higher net margin
ISSC
ISSC
1416.9% more per $
ISSC
18.6%
-1398.3%
RNA
More free cash flow
ISSC
ISSC
$163.9M more FCF
ISSC
$7.0M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
42.5%
ISSC

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
ISSC
ISSC
RNA
RNA
Revenue
$21.8M
$12.5M
Net Profit
$4.1M
$-174.4M
Gross Margin
54.5%
Operating Margin
28.9%
-1513.5%
Net Margin
18.6%
-1398.3%
Revenue YoY
36.6%
434.0%
Net Profit YoY
451.4%
-117.0%
EPS (diluted)
$0.22
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ISSC
ISSC
RNA
RNA
Q4 25
$21.8M
Q3 25
$22.2M
$12.5M
Q2 25
$24.1M
$3.8M
Q1 25
$21.9M
$1.6M
Q4 24
$16.0M
$3.0M
Q3 24
$15.4M
$2.3M
Q2 24
$11.8M
$2.0M
Q1 24
$10.7M
$3.5M
Net Profit
ISSC
ISSC
RNA
RNA
Q4 25
$4.1M
Q3 25
$7.1M
$-174.4M
Q2 25
$2.4M
$-157.3M
Q1 25
$5.3M
$-115.8M
Q4 24
$736.2K
$-102.3M
Q3 24
$3.2M
$-80.4M
Q2 24
$1.6M
$-70.8M
Q1 24
$1.2M
$-68.9M
Gross Margin
ISSC
ISSC
RNA
RNA
Q4 25
54.5%
Q3 25
63.2%
Q2 25
35.5%
Q1 25
51.4%
Q4 24
41.4%
Q3 24
55.4%
Q2 24
53.4%
Q1 24
52.0%
Operating Margin
ISSC
ISSC
RNA
RNA
Q4 25
28.9%
Q3 25
37.0%
-1513.5%
Q2 25
14.6%
-4448.7%
Q1 25
31.8%
-8360.9%
Q4 24
8.4%
-4069.6%
Q3 24
28.4%
-4200.9%
Q2 24
17.3%
-4040.4%
Q1 24
15.3%
-2178.6%
Net Margin
ISSC
ISSC
RNA
RNA
Q4 25
18.6%
Q3 25
32.0%
-1398.3%
Q2 25
10.1%
-4089.3%
Q1 25
24.3%
-7360.0%
Q4 24
4.6%
-3439.5%
Q3 24
20.7%
-3441.7%
Q2 24
13.2%
-3461.8%
Q1 24
11.3%
-1943.4%
EPS (diluted)
ISSC
ISSC
RNA
RNA
Q4 25
$0.22
Q3 25
$0.40
$-1.27
Q2 25
$0.14
$-1.21
Q1 25
$0.30
$-0.90
Q4 24
$0.04
$-0.80
Q3 24
$0.18
$-0.65
Q2 24
$0.09
$-0.65
Q1 24
$0.07
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ISSC
ISSC
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$8.3M
$350.2M
Total DebtLower is stronger
$23.8M
Stockholders' EquityBook value
$68.7M
$1.9B
Total Assets
$109.9M
$2.1B
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ISSC
ISSC
RNA
RNA
Q4 25
$8.3M
Q3 25
$2.7M
$350.2M
Q2 25
$601.8K
$243.9M
Q1 25
$1.2M
$254.2M
Q4 24
$604.6K
$219.9M
Q3 24
$539.0K
$370.2M
Q2 24
$521.0K
$575.8M
Q1 24
$574.1K
$471.4M
Total Debt
ISSC
ISSC
RNA
RNA
Q4 25
$23.8M
Q3 25
$24.4M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ISSC
ISSC
RNA
RNA
Q4 25
$68.7M
Q3 25
$64.6M
$1.9B
Q2 25
$56.8M
$1.2B
Q1 25
$53.5M
$1.3B
Q4 24
$47.8M
$1.4B
Q3 24
$46.6M
$1.5B
Q2 24
$43.2M
$1.2B
Q1 24
$41.4M
$830.9M
Total Assets
ISSC
ISSC
RNA
RNA
Q4 25
$109.9M
Q3 25
$103.4M
$2.1B
Q2 25
$91.8M
$1.4B
Q1 25
$89.9M
$1.5B
Q4 24
$81.3M
$1.6B
Q3 24
$82.4M
$1.6B
Q2 24
$59.8M
$1.3B
Q1 24
$57.6M
$951.5M
Debt / Equity
ISSC
ISSC
RNA
RNA
Q4 25
0.35×
Q3 25
0.38×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ISSC
ISSC
RNA
RNA
Operating Cash FlowLast quarter
$8.2M
$-156.2M
Free Cash FlowOCF − Capex
$7.0M
$-156.9M
FCF MarginFCF / Revenue
32.3%
-1257.6%
Capex IntensityCapex / Revenue
5.1%
5.7%
Cash ConversionOCF / Net Profit
2.01×
TTM Free Cash FlowTrailing 4 quarters
$12.3M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ISSC
ISSC
RNA
RNA
Q4 25
$8.2M
Q3 25
$3.0M
$-156.2M
Q2 25
$7.2M
$-199.7M
Q1 25
$1.3M
$-124.8M
Q4 24
$1.8M
$-99.9M
Q3 24
$445.3K
$-65.6M
Q2 24
$934.1K
$-65.0M
Q1 24
$201.1K
$-70.4M
Free Cash Flow
ISSC
ISSC
RNA
RNA
Q4 25
$7.0M
Q3 25
$2.0M
$-156.9M
Q2 25
$3.5M
$-203.0M
Q1 25
$-267.7K
$-128.6M
Q4 24
$1.6M
$-103.8M
Q3 24
$299.5K
$-67.3M
Q2 24
$730.8K
$-65.5M
Q1 24
$75.4K
$-71.3M
FCF Margin
ISSC
ISSC
RNA
RNA
Q4 25
32.3%
Q3 25
8.8%
-1257.6%
Q2 25
14.6%
-5277.1%
Q1 25
-1.2%
-8174.3%
Q4 24
9.9%
-3491.0%
Q3 24
1.9%
-2881.8%
Q2 24
6.2%
-3204.6%
Q1 24
0.7%
-2012.3%
Capex Intensity
ISSC
ISSC
RNA
RNA
Q4 25
5.1%
Q3 25
4.5%
5.7%
Q2 25
15.3%
86.9%
Q1 25
7.1%
238.6%
Q4 24
1.6%
131.7%
Q3 24
0.9%
72.9%
Q2 24
1.7%
26.0%
Q1 24
1.2%
25.8%
Cash Conversion
ISSC
ISSC
RNA
RNA
Q4 25
2.01×
Q3 25
0.42×
Q2 25
2.95×
Q1 25
0.24×
Q4 24
2.50×
Q3 24
0.14×
Q2 24
0.60×
Q1 24
0.17×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ISSC
ISSC

Products$13.6M62%
Services$8.2M38%

RNA
RNA

Segment breakdown not available.

Related Comparisons